Effects of Clopidogrel on Serum Vasodilator-Stimulated Phosphoprotein Phosphorylation Level in Patients with Coronary Artery Disease
10.3969/j.issn.0253-9896.2014.11.025
- VernacularTitle:氯吡格雷对冠心病患者血清血管扩张刺激磷蛋白磷酸化水平的影响
- Author:
Ping MA
;
Qiaohong MA
;
Zhijun LIU
;
Yumin QIU
;
Qingbin XU
- Publication Type:Journal Article
- Keywords:
coronary disease;
clopidogrel;
vasodilator-stimulated phosphoprotein;
platelet activation
- From:
Tianjin Medical Journal
2014;(11):1135-1137
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the changes of platelet activity before and after anti-platelet treatment in pa?tients with coronary heart disease, and their responsiveness to clopidogrel through detecting the phosphorylation levels of va?sodilator stimulated phosphoprotein (VASP). Methods Twenty-eight cases of healthy people were selected as control group . Patients with chronic stable angina pectoris (CSA, n=95) were randomly divided into A (48 cases) group and B (47 cases) group,and were given clopidogrel 75 mg/d or 150 mg/d respectively;Patients with non ST segment elevation acute coronary syndrome (NST-ACS, n=67) were all given 300 mg loading dose of clopidogrel at the first time, then randomly divid?ed into C (33 cases) group and D (34 cases) group, and given clopidogrel 75 mg/d and 150 mg/d respectively. Blood were tak?en to examine the phosphorylation levels of serum VASP by ELISA before taking clopidogrel, at time point of loading dose and the fifth day of clopidogrel administration . Results Before treatment, phosphorylation levels of serum VASP were low?er in A, B, C, D groups than those in the normal control group(P<0.05). After treatment of clopidogrel for 5 days: ① In group A and group B ,phosphorylation levels of serum VASP did not change compared to that before treatment (P>0.05).②In group C and group D, phosphorylation levels of serum VASP were significantly increased at loading dose and the fifth day of clopidogrel administration than those before treatment (P<0.05), but there were no significant differences in phosphory?lation level of VASP was lower group between group C and group D after serum treatment (P > 0.05). Conclusion The phosphorylation level of serum VASP was lower in patients with coronary heart disease than that in normal control group. Clopidogrel can improve the phosphorylation level of serum VASP in NST-ACS patients .
